Triple therapy aims to turn inoperable bowel cancer into surgical candidates

NCT ID NCT07446465

Not yet recruiting Disease control Sponsor: Ye Xu Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining chemotherapy (FOLFOX), a targeted drug (fruquintinib), and an immunotherapy (serplulimab) can shrink advanced colorectal cancer enough to allow surgery. About 42 adults with a specific genetic type (pMMR/MSS) who have not had prior treatment will receive the combination. The goal is to see if more patients can become eligible for surgery and how well the tumors respond.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (LOCALLY ADVANCED OR METASTATIC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER (LOCALLY ADVANCED OR METASTATIC) COLORECTAL CANCER MICROSATELLITE STABLE (MSS)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan University Shanghai Cancer Center

Shanghai, Xuhui, China

Contact Phone: •••-•••-•••• Email: •••••@•••••